Cell therapy for solid tumors: insights into an evolving landscape

Logo

Cell therapy for solid tumors: insights into an evolving landscape

While solid tumors pose a formidable challenge due to their complex microenvironment and heterogeneity, advances in cell and gene therapy are increasingly demonstrating potential to overcome these barriers. Explore this curated collection of talks that delve into the latest strategies and clinical data driving this therapeutic revolution.

The long journey of CAR T cells: from hematology to oncology and autoimmune disorders

Prof. Franco Locatelli, MD, from the IRCCS Ospedale Pediatrico Bambino Gesù in Rome, Italy, discusses the journey and evolution of CAR T cells in therapeutic use, from treating hematological and oncological conditions to their more recent applications in autoimmune disorders.

Prof. Franco Locatelli, MD @ MACS Cell and Gene Therapy Days 2025

Prof. Franco Locatelli, Head of the Department of Paediatric Haematology and Oncology and Cell and Gene Therapy, Bambino Gesù Children’s Hospital, Rome, Italy

Prof. Franco Locatelli, MD

Head of Pediatric Hematology and Oncology and Cell and Gene Therapy at Bambino Gesù Children's Hospital, Rome, Italy

Franco Locatelli is Full Professor of Pediatrics at the Catholic University of the Sacred Heart in Rome and Head of the Department of Paediatric Haematology and Oncology and Cell and Gene Therapy at the Bambino Gesù Children’s Hospital in Rome. Prof. Locatelli was President of the Italian Association for Pediatric Haematology/Oncology (AIEOP) from 2004 to 2006 and he served as Chair of the European EWOG-MDS consortium from 2005 to 2011. Prof. Locatelli leads the largest allogeneic hematopoietic stem cell transplantation program in Italy.

He is an expert in pediatric hematological malignant and non-malignant disorders. Prof. Locatelli currently serves as chairperson of the current diagnostic and treatment protocol for children with newly diagnosed acute myeloid leukemia and is the Italian coordinator of the consortium on relapsed acute lymphoblastic leukemia. In addition, Prof. Locatelli is chairperson of the international protocol of chemotherapy-free treatment of childhood acute promyelocytic leukemia, the coordinator of AIEOP’s Acute Non-Lymphoblastic Leukemia Working Group and is the principal investigator of the forthcoming academic global study on conditioning hematopoietic stem cell transplantation in acute lymphoblastic leukemia in children.

During his career, Prof. Locatelli has provided relevant contributions to the study of childhood leukemia, myelodysplastic syndromes, thalassemia, innate immunity, immune reconstitution after transplantation, tumor immunology, induction of tolerance towards alloantigens and anti-viral cellular immunity. His current main research interests are CAR T cells for both B-cell malignancies, brain neoplasia and solid tumors (neuroblastoma), and gene therapy/genome editing for hemoglobinopathies.

Prof. Locatelli is the author or co-author of 1419 peer-reviewed articles published in international journals (including New England Journal of Medicine, JAMA, Nature, Nature Genetics, Nature Communications, The Lancet, Lancet Haematology, Lancet Oncology, Lancet Respiratory Medicine, Journal of Clinical Oncology, Journal of Experimental Medicine, Blood, Cancer Research, Leukemia, etc.). With 69,840 citations, he has an H-index of 125 (Scopus source). Since February 2019, Prof. Locatelli is serving as President of the National Council of Health (Consiglio Superiore di Sanità). In December 2021, Prof. Locatelli was nominated 1st Class/Knight Grand Cross (Cavaliere di Gran Croce) by the President of the Italian Republic. Prof. Locatelli was awarded an Honoris Causa Degree in Medicine Biotechnology, by the University of Modena and Reggio Emilia, in March 2025.

Implementation of a Phase I clinical trial to test CAR T cells against ALK in refractory/relapsed neuroblastoma

Selection of the best tumor antigen is critical for the therapeutic success of chimeric antigen receptor (CAR) T cells in hematologic malignancies and solid tumors. The anaplastic lymphoma kinase (ALK) receptor is expressed by most neuroblastomas while virtually absent in most normal tissues. ALK is an oncogenic driver in neuroblastoma and ALK inhibitors show promising clinical activity.

We have developed ALK.CAR T cells that show potent efficacy in monotherapy against neuroblastoma with high ALK expression without toxicity. For neuroblastoma with low ALK expression, a combination with ALK inhibitors specifically potentiates ALK.CAR T cells but not GD2.CAR T cells. Mechanistically, ALK inhibitors impair tumor growth and upregulate the expression of ALK, thereby facilitating the activity of ALK.CAR T cells against neuroblastoma. Based on these results, we have implemented a Phase I clinical trial to treat patients with refractory/relapsed neuroblastoma. Patients will be treated with ALK.CAR T cells alone or eventually in combination with lorlatinib. We envision that while neither ALK inhibitors nor ALK.CAR T cells will likely be sufficient as monotherapy in neuroblastoma with low ALK density, their combination will specifically enhance therapeutic efficacy. The potential toxicities of ALK.CAR T cells will also be discussed.

Roberto Chiarle, MD @ Miltenyi Biotec Cell and Gene Therapy Days 2024

Roberto Chiarle, MD, Professor of Pathology, Turin University, Italy / Boston Children's Hospital, Dana Farber Cancer Institute, USA

Roberto Chiarle, MD

Professor of Pathology, Turin University, Italy / Boston Children's Hospital, Dana Farber Cancer Institute, USA

Dr. Chiarle received his MD degree from the University of Torino, Italy, and is currently Professor of Pathology at the University of Torino Medical School as well as Professor of Pathology at Harvard Medical School. He has been recently appointed Director of the Hematopathology Unit at the European Research Institute (IEO) in Milan in 2022.

He has won several national and international awards, including awards from the Italian National Academy of Science, two European Research Council (ERC) grants, an AICR-UK award, several NIH grants and grants from the LUNGevity Foundation, V Foundation, the Ellison Foundation, the Bridge Project and others.

One major research interest has been to study the mechanisms and pathways of tumor formation activated by the ALK oncogene, as well as the development of innovative therapies for ALK-positive cancers, such as an ALK-specific cancer immunotherapy. Recently, the group has developed an ALK vaccine that instructs the immune system to recognize and eliminate ALK-positive lymphoma and lung cancer cells as well as CAR T cells to target ALK+ tumors including neuroblastoma.

Challenges of cellular immunotherapy for glioblastoma and other solid tumors

Chimeric antigen receptor (CAR) T cell and other cellular immunotherapies have revolutionized treatment of many hematologic/lymphoid malignancies, including replacement of traditional cytotoxic chemotherapy and radiotherapy approaches as frontline therapy. Outcomes with such agents for solid tumors have been less dramatic, and overall modest at best.

Glioblastoma (GBM), the most common primary malignant neoplasm of the central nervous system with a median survival of 15 months, is recognized as a paradigmatic immune-refractory solid tumor. Several factors have contributed to failure of immunotherapy approaches including immune checkpoint modulators and adoptive cellular therapies to improve survival for GBM including a tumor microenvironment (TME) characterized by a paucity of effector T cells and a dominance of suppressive myeloid cells, tumor cell secretion of a host of immunosuppressive molecules that prevent activation or abrogate anti-tumor immune responses as well as challenges posed by the physiologically protective blood brain barrier. Nonetheless, strategies to circumvent some of these hurdles including the development of promising and potentially complementary combinatorial immunotherapy approaches for GBM are being pursued with encouraging, albeit preliminary, outcomes. In this talk, we will review some of the challenging features of the GBM TME and preliminary results of ongoing cellular therapies and planned studies.

David Reardon, MD @ Miltenyi Biotec Cell and Gene Therapy Days 2024

David Reardon, MD, Clinical Director, Center for Neuro-oncology, Dana Farber Cancer Institute, Boston, MD, USA

David Reardon, MD

Clinical Director at the Center for Neuro-oncology, Dana Farber Cancer Institute, USA

David A. Reardon, MD, is a Professor of Medicine at Harvard Medical School and currently serves as Clinical Director of the Center for Neuro-Oncology at the Dana-Farber Cancer Institute. He previously served as the Associate Deputy Director of the Preston Robert Tisch Brain Tumor Center at Duke University Medical Center for eleven years.

He completed his residency at John Hopkins Hospital in Maryland, USA, and was awarded a fellowship at the University of Michigan. Dr. Reardon is an active researcher with special interests in the design and implementation of clinical trials for neuro-oncology and the preclinical evaluation of promising therapeutics for central nervous system tumors.

His work includes using innovative clinical therapeutic agents to improve outcomes for patients with brain and spinal tumors, with a particular focus on immunotherapeutics. He has also led investigations of molecular-targeting agents, anti-angiogenic reagents, cytotoxins, and other biologically-based therapies.

Dr. Reardon has published over 290 peer-reviewed manuscripts. He received the R. Wayne Rundles Award for Excellence in Cancer Research as well as the Award for Excellence in Adult Clinical Research from the Society for Neuro-Oncology in 2015 and 2016. He also served as the tenth president of the Society for Neuro-Oncology from 2013-2015.

Automated and streamlined manufacturing of TIL therapies

This webinar discusses advancements in the use of tumor-infiltrating lymphocytes (TILs) for cancer therapy, a field recently endorsed by the FDA. Despite the promise, traditional TIL manufacturing is complex, prone to error, and difficult to scale due to manual processes. The webinar introduces a novel, automated TIL manufacturing process designed to streamline production in a single, closed device. Dr. Ian Hardy from Miltenyi Biotec will detail this new system and its clinical applications, while Professor Lars Ny from the University of Gothenburg will discuss early results in using TILs for targeted therapy in liver metastases of ocular melanoma.

Webinar given by Ian Hardy, PhD and Prof. Lars Ny, MD, PhD in 2024

Prof. Lars Ny, MD, PhD

Deputy Head of the Institute of Clinical Sciences, University of Gothenburg

Lars Ny is a professor of Immuno-Oncology at the University of Gothenburg and Senior Consultant in Oncology at Sahlgrenska University Hospital in Sweden. He is Head of the Melanoma Oncology Service and deputy director of the Institute of Clinical Sciences, Sahlgrenska Academy.

As a dual specialist in clinical pharmacology and oncology, Lars supervises graduate students and postdoctoral fellows and teaches at both undergraduate and postgraduate levels. His research focuses on cell therapy for metastatic melanoma. Lars has co-ordinated more than 20 clinical trials and published more than 100 peer-reviewed articles (h-index 40). He has been an editor for Acta Oncologica since 2022.

Ian Hardy, PhD

Director of T Cell Therapy for Personalized Immunotherapy, Miltenyi Biotec

Ian Hardy is Director of T Cell Therapy for Personalized Immunotherapy at Miltenyi Biotec, an innovative globally acting company that provides products and services that drive biomedical research and boost cell and gene therapy. Ian helped launch the CliniMACS Prodigy® TRT Process and his group now works to help Miltenyi Biotec bring innovative T cell therapies from conceptualization to preclinical validation and clinical translation.

BNT211-01: Interim results from a repeat dose escalation study of CLDN6 CAR T cells manufactured with an automated process ± a CLDN6-encoding CAR T cell-amplifying RNA vaccine (CARVac)

Despite the success of CAR T cell therapies in hematologic malignancies, the application of these therapies in solid tumors has met several challenges. BNT211 is an investigational CAR T cell therapy targeting Claudin-6 (CLDN6), an oncofetal antigen that is expressed in multiple solid tumor types but is absent in healthy adult tissues. BNT211-01 (NCT04503278) is a first-in-human, Phase I clinical trial investigating CLDN6 CAR T with or without CLDN6-encoding CAR T cell amplifying RNA vaccine (CARVac) in patients with relapsed/refractory CLDN6-positive solid tumors. This talk will discuss the rationale of targeting CLDN6, summarize the preclinical studies that support the concept of CARVac-driven expansion of CAR T cells, and share interim clinical data from the BNT211-01 Phase I study.

Heidi Gillenwater, MD @ Miltenyi Cell and Gene Therapy Days 2024

Heidi Gillenwater, MD, Vice President Clinical Development, Portfolio CGT, BioNTech, Germany

Heidi Gillenwater, MD

Vice President Clinical Development, Portfolio CGT, BioNTech, Germany

Heidi Gillenwater, MD, is a medical oncologist with a long history of cellular therapy clinical development. She is currently VP Clinical Development, Cell and Gene Therapy at BioNTech. Prior to joining BioNTech, she served as VP Clinical Development at Lyell Immunopharma, where she was responsible for the development of a ROR1-directed CAR T cell therapy in ROR1 positive solid tumors as well as TIL therapy for patients with solid tumors. Prior to Lyell, she was at Juno/Celgene/BMS where she was involved in the development of Bryenzi.

Hypoxia-sensing CAR T to focus the fight on solid cancers

On target off-tumor activation of chimeric antigen receptor T cell (CAR T) immunotherapies can result in dose and treatment limiting toxicities in patients. Unfortunately, tumor-specific CAR targets for solid cancers are scarce. We have been investigating opportunities for exploiting hypoxia, which represents a selective feature of most solid tumors, as a trigger for CAR T activation. We developed a stringent hypoxia-sensing CAR T platform technology called ‘HypoxiCAR’, which delivers tumor-restricted CAR expression and activation. In preclinical models, HypoxiCAR successfully provides anti-tumor efficacy while circumventing systemic toxicities of this therapy.

James Arnold, DPhil @ Miltenyi Biotec Cell and Gene Therapy Days 2023

James Arnold, DPhil

Reader and Head of Tumour Immunology Group, Kings College London, UK / CSO Korecyte Bio, UK

James Arnold, DPhil, started his career at the University of Oxford for his DPhil where he studied the complement system under the supervision of Dr. Bob Sim. After his DPhil, James went on to study with Professor Douglas Fearon at the University of Cambridge in the CRUK Cambridge Research Institute.

It was under Professor Fearon’s mentorship that James became interested in tumor immunology and discovered that a population of cancer-associated fibroblasts was pivotal to suppressing anti-tumor immunity using murine models of cancer. In 2010, James became a Fellow of the Cancer Research Institute (NY), Irvington Institute Research Program, and in 2012, moved to King’s College London to establish the Tumor Immunology Group. James’ academic group focuses on translational approaches to harness the anti-tumor immune response against cancer and developed a hypoxia-sensing CAR-T platform to limit off-tumor activation of these cells for the treatment of solid cancers. James was appointed to the academic position of Reader (Associate Professor) in 2021. In 2023, James became co-founder and Chief Scientific Officer of Korecyte Bio, a cellular immunotherapy biotech focused on developing and pioneering hypoxia-sensing CAR approaches towards clinical translation.